SLC5A2 and hydrops fetalis: Ameta-analysis of these two trials concluded that SGLT2 inhibition, when added tooptimal medical therapy in patients with HFrEF, reduced all-cause (HR 0.87, 95%CI 0.77–0.98) and cardiovascular death (HR 0.86, 95% CI 0.76–0.98),hospitalizations for HF (HR 0.69, 95% CI 0.62–0.78), and improved renaloutcomes.